Page 36 - Dupilumab Development Program News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Sanofi: Dupixent (dupilumab) SmPC updated with long-term data reinforcing well-established safety profile in adults with moderate-to-severe atopic dermatitis

Sanofi: Dupixent (dupilumab) SmPC updated with long-term data reinforcing well-established safety profile in adults with moderate-to-severe atopic dermatitis in adults with moderate-to-severe atopic dermatitis Dupixent is the first and only available systemic treatment for atopic dermatitis that has been studied in adults for up to 3 years in a Phase 3 trial PARIS and TARRYTOWN, N.Y. - June 28 , 2021- Long-term safety data from a study of adults with moderate-to-severe atopic dermatitis treated with Dupixent will be added to the Dupixent Summary of Product Characteristics (SmPC) following a positive opinion issued by the European Medicines Agency s Committee for Medicinal Products for Human Use.

United statesFrance generalEva schaefer jansenArnaud delepineSuzanne grecoFelix lauscherMark hudsonFara berkowitzHannah kwaghNathalie phamSally bainExchange commissionRegeneron pharmaceuticals incRegeneron genetics centerDupilumab development programTeva pharmaceutical industries ltd

Pivotal Data at ATS 2021 Show Dupixent® (dupilumab) Significantly Reduced Asthma Attacks and Improved Lung Function in Children

Pivotal Data at ATS 2021 Show Dupixent® (dupilumab) Significantly Reduced Asthma Attacks and Improved Lung Function in Children
apnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from apnews.com Daily Mail and Mail on Sunday newspapers.

United statesFrance generalVanderbilt universityMonroe carell jrLeonardb bacharierPediatric asthma researchRegeneron pharmaceuticals incRegeneron genetics centerDupilumab development programAmerican thoracic society international conferenceTeva pharmaceutical industries ltdExchange commissionChildren hospital at vanderbilt university medical centerThoracic society international conferenceBreaking newsClinical trial results

Sanofi: New Dupixent (dupilumab) analyses reinforce long-term safety and efficacy profile in patients with atopic dermatitis as young as 6 years

Sanofi: New Dupixent (dupilumab) analyses reinforce long-term safety and efficacy profile in patients with atopic dermatitis as young as 6 years as young as 6 years Nearly 30 data presentations at AAD and ESPD across clinical and real-world settings, including the impact of Dupixent on disease measures in uncontrolled moderate-to-severe atopic dermatitis Late-breaking Phase 2 data for rilzabrutinib, an investigational therapy for pemphigus vulgaris, a rare, debilitating autoimmune disease, to be presented at AAD PARIS - April 23, 2021 - New analyses from Dupixent (dupilumab) trials evaluated infection incidence reduction and reinforced the need for no laboratory monitoring in patients six years and older with moderate-to-severe atopic dermatitis. Additional analyses evaluated response rates across a broad population, and the impact of Dupixent on disease extent and severity, quality of life (QoL), and itch. These and other data from real-world settings and clinical trials, in

United statesFrance generalEva schaefer jansenSebastien barbarotSuzanne grecoArnaud delepineJonathani silverbergFelix lauscherAmys pallerDedeef murrellStephan weidingerFara berkowitzMark boguniewiczSally bainNaimish patelAndrew blauvelt

New Dupixent® (dupilumab) Analyses at Two Upcoming Dermatology Congresses Reinforce Long-term Safety and Efficacy Profile in Patients with Atopic Dermatitis as Young as 6 Years

Share this article TARRYTOWN, N.Y., April 23, 2021 /PRNewswire/ Nearly 30 data presentations at AAD and ESPD highlight the impact of Dupixent on disease measures including rapid itch relief and sustained improvement in disease severity, as well as quality of life in clinical and real-world settings Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that new analyses of Dupixent ® (dupilumab) in patients as young as 6 years with moderate-to-severe atopic dermatitis will be presented at the American Academy of Dermatology Annual Meeting (AAD VMX 2021) from April 23-25, and at the 20 th European Society for Pediatric Dermatology Annual Meeting (ESPD 2021) from May 12-14. Atopic dermatitis is a debilitating disease that spares no age group and is associated with persistent itch and painful lesions that can impair quality of life, affecting the entire family, said Bola Akinlade, M.D., Vice President, Clinical Sciences, Immunology and Inflammation, at Regeneron

United statesSebastien barbarotGil yosipovitchJonathani silverbergGeorged yancopoulosAmys pallerMark hudsonRegeneron velocimmuneStephan weidingerHannah kwaghMark boguniewiczAndrew blauveltAmerican academy of dermatology annual meetingWorldwide survey shows that atopic dermatitis isTeva pharmaceutical industries ltdDupilumab treatment improves health

Investegate |Sanofi Announcements | Sanofi: New Dupixent® (dupilumab) analyses reinforce long-term safety and efficacy profile in patients with atopic dermatitis as young as 6 years

Investegate |Sanofi Announcements | Sanofi: New Dupixent® (dupilumab) analyses reinforce long-term safety and efficacy profile in patients with atopic dermatitis as young as 6 years
investegate.co.uk - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from investegate.co.uk Daily Mail and Mail on Sunday newspapers.

United statesFrance generalEva schaefer jansenSebastien barbarotSuzanne grecoArnaud delepineJonathani silverbergFelix lauscherAmys pallerDedeef murrellStephan weidingerFara berkowitzMark boguniewiczSally bainNaimish patelAndrew blauvelt